SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas is currently trending as investors monitor a highly anticipated earnings report and potential short squeeze, given that nearly half the float is held by short sellers. The community remains deeply divided, with bulls highlighting strong revenue growth and backlog expansion, while bears cite ongoing dilution and concerns regarding company profitability.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is experiencing high volatility as investors weigh a significant earnings miss and project delays against a record-breaking contract backlog and ambitious revenue guidance. The community remains deeply divided, with bulls pointing to the company's long-term growth potential and institutional demand, while bears emphasize concerns over cash burn, share dilution, and the recent operational setbacks.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is capturing significant community attention ahead of their earnings call, with investors highlighting record revenue growth and a strong cash position as key catalysts for a potential rerating. The stock is a primary focus for traders speculating on the company's ability to secure government contracts and validate its quantum technology roadmap against broader sector peers.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco is currently trending following a significant stock price decline after earnings, as the market reacted negatively to margin concerns despite a revenue and EPS beat. Investors are debating whether the sell-off is a short-term overreaction to margin pressure or a necessary repricing of a company that is being compared to broader AI sector volatility.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumble is trending as investors respond to record revenue growth and the strategic integration of Quake AI, fueling speculation of a potential short squeeze given the stock's elevated short interest. Community discussion is heavily focused on the company's expanding data center capacity and the anticipated revenue ramp from recent hardware acquisitions, with many betting that institutional interest will force a re-rating of the stock.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is facing significant downward pressure following Q2 earnings that missed revenue and margin expectations, sparking intense debate among investors regarding its high valuation and future growth potential. While some in the community view the post-earnings selloff as a compelling buying opportunity for a long-term AI play, others remain skeptical, citing concerns over insider share lockup expirations and the company's hardware performance in a competitive sector.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending as investors react to raised guidance and a new multi-year contract with a major dialysis provider, fueling debate about whether this represents a true operational milestone or a temporary pop. While sentiment remains bullish, long-term holders are actively questioning management's communication and the potential for sustaining share price gains in the post-TDAPA reimbursement environment.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is seeing a massive surge in volume and investor excitement, driven by a strong quarterly earnings report that significantly beat revenue expectations and triggered bullish sentiment. The community is actively discussing the stock's potential for a short squeeze, its long-term pipeline value, and the possibility of a major pharmaceutical acquisition.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is currently trending as investors monitor it alongside broader AI infrastructure plays like Super Micro and Lenovo, fueled by strong sector-wide demand and analyst commentary around server backlogs. Community discourse remains focused on the company's relative valuation and its positioning as a stable leader compared to more volatile peers in the data center hardware space.

Coherent Corp. engages in the development, refinement, manufacturing, and marketing of engineered materials, opto-electronic components and devices, and lasers for use in the industrial, communications, electronics, and instrumentation markets. It operates through the following segments: Networking, Materials, and Lasers. The Networking segment leverages compound semiconductor technology platforms and deep knowledge of end-user applications. The Materials segment markets engineered materials and optoelectronic devices. The Lasers segment serves industrial customers in semiconductor capital equipment, display capital equipment, precision manufacturing, and aerospace and defense, as well as instrumentation customers in life sciences and scientific research. The company was founded by Carl J. Johnson in 1971 and is headquartered in Saxonburg, PA.

Coherent Corp

Coherent Corp is experiencing heightened investor attention following a strong earnings report that beat analyst estimates and solidified its position as a key player in the AI infrastructure buildout. Despite the positive results, the stock is seeing price volatility as investors weigh the company's impressive outlook against broader market sell-offs in the optical networking sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ADC Therapeutics Q2 2026 Earnings Call Transcript

On Thursday, ADC Therapeutics (NYSE:ADCT) discussed second-quarter financial results during its earnings call. The full transcript is provided below.
This content is powered by Benzinga APIs. For comprehensive financialread more...

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates PR Newswire LAUSANNE, Switzerland, Aug. 13, 2026 Second quarter 2026 net product revenue of $18.6 million...

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of +35.29% and +13.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 PR Newswire LAUSANNE, Switzerland, Aug. 6, 2026 LAUSANNE, Switzerland, Aug. 6, 2026 /PRNewswire/ -- ADC...

Alkermes (ALKS) Reports Break-Even Earnings for Q2

Alkermes (ALKS) delivered earnings and revenue surprises of +100.00% and +9.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics Announces New Employee Inducement Grant

ADC Therapeutics Announces New Employee Inducement Grant ADC Therapeutics Announces New Employee Inducement Grant PR Newswire LAUSANNE, Switzerland, July 1, 2026 LAUSANNE, Switzerland, July 1, 2026 /PRNewswire/ --ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the...

ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA Combination Trial

ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA Combination Trial ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA Combination Trial PR Newswire LAUSANNE, Switzerland, June 30, 2026 100 r/r DLBCL patients treated at the selected 150...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT PR Newswire NEW YORK, June 25, 2026 NEW YORK, June 25, 2026 /PRNewswire...

ADC Therapeutics To Cut About 17% Of Its Staff – A Look At Some Key Details

Equity

ADC Therapeutics expects to generate annualized cost savings of about $10 million and incur one-time pre-tax charges of about $3 million.

ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA Growth Opportunities and Regulatory Priorities

ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA Growth Opportunities and Regulatory Priorities ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA Growth Opportunities and Regulatory Priorities PR Newswire LAUSANNE, Switzerland, June 24, 2026 Planned ~17...

$ADCT Q2 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.11 up 78.00% YoY
• Reported revenue of $19.25M up 2.17% YoY

Stocktwits

Adc Therapeutics SA

 Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.11 up 78.00% YoY
• Reported revenue of $19.25M up 2.17% YoY

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

$ADCT Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.21 up 41.67% YoY
• Reported revenue of $20.85M down -9.47% YoY
• ADC Therapeutics expects LOTIS-5 Phase 3 topline data in Q2 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end, and maintains an expected cash runway at least into 2028.

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info